Matthew L. Kaplan

Board Director

Director

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 1 buy · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (3 ops.)

€105k

▼ Sales (0 ops.)

—

Latest filing published 06 Nov 2025 for Nuvectis Pharma, Inc., €56k.

Filing timeline

BuySale

Matthew L. Kaplan

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

50%

T+90 mean return

-2.5%

Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Matthew L. Kaplan: trading record in brief

Matthew L. Kaplan, listed as board member, appears in our data through filings on Nuvectis Pharma, Inc. shares, published by SEC (Form 4). We count 6 filings; the first trade dates from 12 May 2022 and the latest from 5 November 2025.

On the market, this insider has only ever bought: 3 purchases, €105k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 share grants. 2025 to date brings 1 purchase and no sales.

A typical purchase (the median) is worth €31k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 6 November 2025: an open-market purchase of €56k, in Nuvectis Pharma, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.